Management Team

Mr. Stewart is a co-founder and the Chief Executive Officer of Achieve. He is also a director on the Achieve Board of Directors and previously served as Chairman. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single-purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single-purpose central nervous system company, from 2013 to 2014 prior to Brabant Pharma’s acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.

Craig Donnelly is the Chief Operations Officer at Achieve Life Sciences, following his previous position as Achieve’s Executive Vice President, CMC and Regulatory CMC. In this expanded role, Craig will be responsible for optimizing operations efficiency in the company's manufacturing, supply chain, CMC operations and product life-cycle management, while ensuring the company maintains the highest standards of quality and regulatory compliance.  With over 25 years of experience in the biopharmaceutical industry, Craig has expertise in both technical development and regulatory CMC at all stages of development. He formerly held senior roles in CMC and regulatory functions at companies including NuCana, ICON (formerly Mapi), and F. Hoffman-La Roche. He began his career at Pfizer as an analytical chemist before advancing to a project leadership role and served as a Team Leader at Almac Sciences. Craig holds a Bachelor’s with Honors in Chemical and Pharmaceutical Sciences from the University of Sunderland.

Mr. Oki has served as our Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial-stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).

Dr. Mark L. Rubinstein is the Interim Chief Medical Officer at Achieve Life Sciences, bringing more than two decades of experience in clinical medicine, scientific research and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining Achieve, Dr. Rubinstein served as the Head of Medical Affairs at Blip, where he spearheaded the company’s strategy to help smokers and vapers quit through FDA-approved medications and digital support tools. He was also Vice President of Global Scientific Affairs at Juul Labs, where he led efforts to prevent youth usage of nicotine products. He is Professor Emeritus of Pediatrics at the University of California, San Francisco (UCSF), where his NIH-funded research advanced understanding of adolescent nicotine addiction and smoking cessation interventions. Dr. Rubinstein earned his M.D. from Yale School of Medicine, completed his Internal Medicine residency at Yale–New Haven Hospital, and is board certified in Internal Medicine and Adolescent Medicine. 

Ms. Jaime Xinos has 25 years of commercial experience in the biotechnology and pharmaceutical industries. She is an inspirational thought leader, highly skilled in translating science into business as well as developing commercial strategies for specialty products across all stages of the product development continuum. Jaime has served as the Chief Commercial Officer at Achieve Life Sciences since October 2024. Prior to this role, she served as the Executive Vice President of Commercial at Achieve since joining in 2017. Prior to Achieve, Ms. Xinos was Vice President, Marketing and Corporate Communications at OncoGenex Pharmaceuticals, an oncology biopharmaceutical company she initially joined as Senior Director, Global Oncology Commercial Development in 2010. Prior to OncoGenex, Ms. Xinos held various commercial roles in marketing, commercial development, and sales at Pfizer, Novartis, and Abbott Laboratories. She holds an undergraduate degree in Communications and a Master of Business Administration (MBA) both from the University of Illinois.